Pfizer: EU approves generic version of Roche cancer drug
(CercleFinance.com) - European regulators approved Pfizer's generic version of Roche's MabThera, a drug used to treat certain cancers and autoimmune diseases.
The European Commission has approved Ruxience for the treatment of conditions including, among others, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the US drugmaker said.
The approval is based on a data showing biosimilarity to the reference product, it said.
Ruxience was recently made available to adult patients in the United States and also launched in Japan earlier this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The European Commission has approved Ruxience for the treatment of conditions including, among others, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the US drugmaker said.
The approval is based on a data showing biosimilarity to the reference product, it said.
Ruxience was recently made available to adult patients in the United States and also launched in Japan earlier this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.